| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 00% | ₹1,324.6 0% | 4,400 | ₹2.6 0% | 5,8750% |
| 00% | ₹1,229.9 0% | 4,500 | ₹2 -50% | 8,2500% |
| 00% | ₹1,136.65 0% | 4,600 | ₹5 0% | 7,5000% |
| 00% | ₹585.95 0% | 4,650 | ₹8 0% | 1250% |
| 1250% | ₹598.05 0% | 4,700 | ₹7.6 0% | 6,0000% |
| 00% | ₹701.05 0% | 4,750 | ₹4.7 -48.35% | 3,3758% |
| 1250% | ₹460 0% | 4,800 | ₹7.45 -22.79% | 3,250-3.70% |
| 00% | ₹617.25 0% | 4,850 | ₹7.45 -46.01% | 6,625-14.51% |
| 00% | ₹870.15 0% | 4,900 | ₹9.85 -36.45% | 7,750-27.90% |
| 00% | ₹538.05 0% | 4,950 | ₹13.25 -33.08% | 9,500-1.29% |
| 250100% | ₹246.55 -14.03% | 5,000 | ₹18.05 -37.54% | 85,1250.29% |
| 7500% | ₹207.85 0% | 5,050 | ₹26.7 -28.89% | 6,8750% |
| 1,1250% | ₹152.05 0% | 5,100 | ₹37.3 -23.56% | 10,250-1.20% |
| 7,0001.81% | ₹128.75 -20.13% | 5,150 | ₹48.25 -28.46% | 87,0000.14% |
| 16,7501.51% | ₹90.4 6.35% | 5,200 | ₹69.45 -21.74% | 41,625-2.05% |
| 17,0001.49% | ₹66 10.46% | 5,250 | ₹93 -24.26% | 13,7500.91% |
| 27,500-1.34% | ₹44.6 1.59% | 5,300 | ₹152 -1.58% | 25,0000% |
| 25,6254.59% | ₹30.05 -3.22% | 5,350 | ₹173.25 0% | 2,5000% |
| 26,6257.03% | ₹22 7.31% | 5,400 | ₹192.1 0% | 4,6250% |
| 3,875-36.73% | ₹13.65 -10.78% | 5,450 | ₹204.95 0% | 8750% |
| 61,875-0.60% | ₹9.05 -8.12% | 5,500 | ₹280 0% | 1,7500% |
| 4,000-25.58% | ₹6.5 -9.72% | 5,550 | ₹311.65 0% | 00% |
| 11,625-7.92% | ₹4.6 -12.38% | 5,600 | ₹361 0% | 5000% |
| 1,3750% | ₹4.8 0% | 5,650 | ₹374.25 0% | 00% |
| 10,6250% | ₹3.15 -3.07% | 5,700 | ₹440.7 0% | 2500% |
| 1,3750% | ₹3.55 0% | 5,750 | ₹465 0% | 1250% |
| 4,875-2.5% | ₹7.15 138.33% | 5,800 | ₹343.5 0% | 00% |
| 8750% | ₹8 0% | 5,850 | ₹516.15 0% | 00% |
| 8,3750% | ₹0.45 0% | 5,900 | ₹400.9 0% | 00% |
| 3,7500% | ₹2.05 5.12% | 6,000 | ₹602.95 0% | 1250% |
| 00% | ₹172.6 0% | 6,100 | ₹529.45 0% | 00% |
| 00% | ₹144.65 0% | 6,200 | ₹600.05 0% | 00% |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
